Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRVNASDAQ:EGRXNASDAQ:SPPINASDAQ:ZIOP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRVAcrivon Therapeutics$1.85-14.0%$4.08$1.30▼$11.51$58.00M1.77117,525 shs643,064 shsEGRXEagle Pharmaceuticals$1.62-10.0%$1.27$0.00▼$6.37$21.04M0.838,270 shs506 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AZIOPZIOPHARM Oncology$1.08$0.77▼$5.95$187.12M1.712.01 million shs2.13 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRVAcrivon Therapeutics+43.33%+58.09%-60.48%-61.19%-77.63%EGRXEagle Pharmaceuticals+44.00%+20.00%+38.46%+190.32%-65.38%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ZIOPZIOPHARM Oncology0.00%0.00%0.00%0.00%0.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACRVAcrivon Therapeutics2.1251 of 5 stars3.52.00.00.02.31.70.6EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRVAcrivon Therapeutics 3.00Buy$23.171,152.25% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/ASPPISpectrum Pharmaceuticals 0.00N/AN/AN/AZIOPZIOPHARM Oncology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EGRX, ZIOP, SPPI, and ACRV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025ACRVAcrivon TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/26/2025ACRVAcrivon TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $19.001/31/2025ACRVAcrivon TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight1/31/2025ACRVAcrivon TherapeuticsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRVAcrivon TherapeuticsN/AN/AN/AN/A$5.38 per shareN/AEGRXEagle Pharmaceuticals$257.55M0.08$4.05 per share0.40N/A∞SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87ZIOPZIOPHARM OncologyN/AN/AN/AN/A$0.58 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRVAcrivon Therapeutics-$60.39M-$2.44N/AN/AN/AN/A-47.95%-43.73%5/13/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/ASPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/AZIOPZIOPHARM Oncology-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/ALatest EGRX, ZIOP, SPPI, and ACRV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AACRVAcrivon Therapeutics-$0.57N/AN/AN/AN/AN/A3/27/2025Q4 2024ACRVAcrivon Therapeutics-$0.69-$0.60+$0.09-$0.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACRVAcrivon TherapeuticsN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AZIOPZIOPHARM OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRVAcrivon TherapeuticsN/A12.7512.75EGRXEagle PharmaceuticalsN/AN/AN/ASPPISpectrum PharmaceuticalsN/A2.712.38ZIOPZIOPHARM Oncology0.183.433.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRVAcrivon Therapeutics71.62%EGRXEagle Pharmaceuticals85.36%SPPISpectrum Pharmaceuticals21.67%ZIOPZIOPHARM Oncology51.03%Insider OwnershipCompanyInsider OwnershipACRVAcrivon Therapeutics8.50%EGRXEagle Pharmaceuticals28.90%SPPISpectrum Pharmaceuticals2.70%ZIOPZIOPHARM Oncology5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRVAcrivon Therapeutics5831.35 million28.49 millionNot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableZIOPZIOPHARM Oncology105216.15 million204.91 millionOptionableEGRX, ZIOP, SPPI, and ACRV HeadlinesRecent News About These CompaniesTCRT stock touches 52-week low at $1.62 amid market challengesJanuary 30, 2025 | msn.comBest Global Universities for OncologySeptember 11, 2024 | usnews.comFDA fast-tracks Merck's cancer blockbuster-in-waitingJuly 28, 2024 | pharmaphorum.comBMS signs $475m cancer immunotherapy deal with DragonflyJuly 23, 2024 | pharmaphorum.comChildhood CancersFebruary 17, 2024 | curetoday.comAlx Oncology Holdings (ALXO)February 10, 2024 | investing.comPediatric Hematology-Oncology FellowshipFebruary 5, 2024 | bcm.eduAlaunos Therapeutics: Other Events, Financial Statements And ExhibitsJanuary 31, 2024 | cbonds.comCG Oncology IncJanuary 31, 2024 | reuters.comOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsDecember 21, 2023 | medscape.comImmuno-OncologyDecember 19, 2023 | ajmc.comWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?December 18, 2023 | markets.businessinsider.comExploring Patient-Centered Handoffs in Surgical OncologyDecember 10, 2023 | medscape.comAssociation of Community Cancer CentersOctober 14, 2023 | ajmc.comOncology News and ResearchSeptember 19, 2023 | news-medical.netWBSPH 2024 - OncologySeptember 15, 2023 | newsweek.comKris on OncologySeptember 6, 2023 | medscape.comGauging Ziopharm's Chances for Positive Sarcoma Drug Trial ResultsAugust 29, 2023 | thestreet.comOncology Cases & QuizzesAugust 14, 2023 | medscape.comZiopharm’s palifosfamide fails in first-line STS…June 21, 2023 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEGRX, ZIOP, SPPI, and ACRV Company DescriptionsAcrivon Therapeutics NASDAQ:ACRV$1.85 -0.30 (-13.95%) As of 04:00 PM EasternAcrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.Eagle Pharmaceuticals NASDAQ:EGRX$1.62 -0.18 (-10.00%) As of 11:17 AM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.ZIOPHARM Oncology NASDAQ:ZIOPZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Eyes Breakout With Earnings on Deck Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited Viking Therapeutics Stock Pops But Struggles to Hold Gains Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Lemonade: Leveraging AI to Underwrite a Path to Profitability 2 Penny Stocks With $10 Potential Congress! Who Traded What During the Tariff-Induced Meltdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
